Income statement
EUR
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 830K | 2M | 1M | 1M | 744K |
| Gross Profit | -7M | -1M | -3M | -5M | -4M |
| Operating Income | -7M | -3M | -6M | -5M | -4M |
| EBITDA | -7M | -4M | -6M | -4M | -4M |
| Net Income | -6M | -4M | -5M | -4M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.532
+0.00% today
1Y Change
+312841.18%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theraclion S.A. (TCLIF) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.53 and up 312841.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +42.8%, EPS growth of +22.0%, a dividend yield of 0.0%. What stands out right now is revenue +42.8%, EPS +22.0%, free cash flow 0.0% with operating margin -424.4% and ROIC -49.8%. Valuation already assumes a fairly strong business story at price/sales 19.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TCLIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCLIF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TCLIF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TCLIF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$744.0K
-49.8% YoY
FY Net Income
-$3.9M
-3.9% YoY
Free Cash Flow
-$3.5M
+14.3% YoY
Revenue Growth
+42.8%
EPS Growth
+22.0%
Gross Margin
-528.2%
Net Margin
-479.8%
Income statement
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 830K | 2M | 1M | 1M | 744K |
| Gross Profit | -7M | -1M | -3M | -5M | -4M |
| Operating Income | -7M | -3M | -6M | -5M | -4M |
| EBITDA | -7M | -4M | -6M | -4M | -4M |
| Net Income | -6M | -4M | -5M | -4M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 8M | 2M | 2M | 2M |
| Total Assets | 11M | 19M | 14M | 12M | 11M |
| Total Liabilities | 11M | 13M | 13M | 13M | 14M |
| Shareholder Equity | -114 | 6M | 545K | -1M | -3M |
| Total Debt | 1M | 2M | 3M | 2M | 11M |
| Net Debt | -3M | -6M | 21K | -99K | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+14.4% YoY
Capital Expenditures
132K
+11.0% YoY
Free Cash Flow
3M
+14.3% YoY
Key ratios
Gross Margin
-528.2%
Operating Margin
-424.4%
Net Margin
-479.8%
ROE
222.0%
Debt / Equity
-1.97x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.